US Adult AIDS Clinical Trials Group

The US Adult AIDS Clinical Trials Group is a United States clinical research network cited for a cross-sectional analysis of hepatitis C virus prevalence among people infected with human immunodeficiency virus. In the supplied material, the group’s significance lies in helping establish HCV/HIV coinfection as a measurable epidemiological and clinical problem rather than an isolated observation.

Identity and Documented Role

The group appears in the volume through a published study on hepatitis C virus prevalence among people infected with human immunodeficiency virus. The citation identifies the work as a cross-sectional analysis conducted within the United States and published in Clinical Infectious Diseases in 2002. The evidence does not provide a roster, governance model, membership structure, or description of the group’s trial infrastructure, so its documented role here is limited to the production and sponsorship context of that prevalence analysis.

Research Context

The group’s study belongs to the book’s wider effort to connect HCV infection with conditions beyond the liver. The volume presents HCV infection as a systemic disease capable of inducing autoimmune, dermatological, and renal disease, and it expressly includes renal complications associated with HCV in patients with HIV infection. Within that framework, the group’s epidemiological contribution helps define the population in which HCV/HIV coinfection becomes clinically relevant to nephrology, dialysis, transplantation, and antiviral decision-making.

Diagnostic and Clinical Significance

The surrounding discussion distinguishes antibody evidence from active infection. HCV infection is diagnosed initially through anti-HCV antibodies detected by third-generation enzyme-linked immunosorbent assays, while chronic active infection requires both anti-HCV positivity and detectable HCV RNA; the text places the molecular detection threshold at approximately 15 IU/ml. This distinction matters for interpreting prevalence research, because a positive antibody result alone does not establish ongoing viral replication or chronic disease. In patients with chronic kidney disease, the evaluation must also consider hepatic injury and extrahepatic manifestations such as cryoglobulinemia-associated vasculitis.

Connection to Kidney Disease and Treatment

The group’s cited prevalence work feeds into a clinical landscape in which HCV can complicate renal disease and its treatment. HCV is described as a major cause of mixed cryoglobulinemia, a systemic vasculitis that may involve proteinuria, hematuria, reduced estimated glomerular filtration rate, nephritic syndrome, nephrotic syndrome, and cryoglobulinemic glomerulonephritis. Antiviral treatment is therefore considered not only to control hepatic infection but also to clear HCV from serum and potentially lessen HCV-associated renal injury. Treatment decisions in chronic kidney disease must balance the severity of kidney and liver disease, treatment risks, and comorbidities such as cardiovascular disease; renal impairment also alters the handling of interferon and ribavirin, with ribavirin contraindicated when creatinine clearance is below 50 ml/min because of the danger of severe anemia.

Place in the Evidence Network

The citation sits alongside work from the Kidney Disease Improving Global Outcomes initiative, the American Association for the Study of Liver Diseases, and other research groups concerned with HCV diagnosis, transmission, treatment, and transplantation. The book also describes how HCV epidemiology changed after the identification of HCV as the principal cause of non-A, non-B hepatitis, how molecular testing separates resolved from active infection, and how direct-acting antiviral drugs later expanded therapeutic options. Against this institutional background, the US Adult AIDS Clinical Trials Group represents the HIV-focused epidemiological strand of the evidence base: its documented contribution is the measurement of HCV burden in an HIV-infected population, a finding that supports subsequent attention to coinfection, renal complications, and individualized therapy.